---
category: news
title: "Charles River inks viral vector production pact for Navega's chronic pain gene therapy"
excerpt: "After charting multiple personalized medicine expansions in recent years, contract manufacturer Charles River Laboratories is back with another gene therapy pactâ€”this time centered on an adeno-associated virus 9 (AAV9) candidate meant to serve as a non-opioid alternative for rare disease patients living with chronic pain."
publishedDateTime: 2024-03-14T09:50:00Z
originalUrl: "https://www.fiercepharma.com/pharma/charles-river-inks-aav-production-pact-navegas-experimental-chronic-pain-gene-therapy"
webUrl: "https://www.fiercepharma.com/pharma/charles-river-inks-aav-production-pact-navegas-experimental-chronic-pain-gene-therapy"
type: article
quality: 46
heat: 46
published: false

provider:
  name: FiercePharma
  domain: fiercepharma.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1146014305.jpg?VersionId=REV7XXd8_LpX._5d6ffrPIgQnFJeGEPj"
    width: 814
    height: 429
    isCached: true

secured: "ZtT6fspmPjHLfze3VFCrKRZw1lOS4Lp5d1z132fKcq5deCJ/d4scTk1liN+V8IVXgEis3qVAs8CrsyoQlMrvQaXHZkr4xy32KkUnfBgh0lf3u8p9rsd1jkdlPcH0Azv3YJ6xkvsbQVSpMkOvZ29srGojjXnWwKDn12QCZ7vL1Ct0JgeGCXeCD1slOcXROiL1ME+bqcTXIjaFZVVYe4YehHeEFHmvF/0wX3/JpKz+/RMGyXP1VM2fwdtle5zwZ754Yg2lzFi+2eA0Sgu7PMSQIQlA68vaH8CdNM3Yqcr0k33CNBJ15rRqHAPMsu17Pymm261AX6kopXTO4GFDNCwlBz3AF7GpuuvFkUc6VJriVVw=;4P3AHcq+TEQsLfT+4ulV0w=="
---

